The FDA is shifting its approach to medical product approvals, moving to allow a single clinical trial instead of the traditional two. FDA Commissioner Marty Makary shared this development, stating that the agency will still require two trials in certain cases, but the standard will now be one trial for most products. This change reflects a growing flexibility within the FDA and acknowledges that many drugmakers have already been submitting only one pivotal trial for approval. Makary emphasized that a well-designed and controlled single trial can offer the same statistical power as two trials. This decision aims to streamline the approval process, potentially speeding up the introduction of new medical products to the market. However, it also raises questions about maintaining safety and efficacy standards, as the historical requirement of two trials was intended to provide an extra layer of assurance. The FDA's willingness to adapt may affect how drug development strategies are planned moving forward.